Genentech Suspends Recruitment in Avastin Trial

Stock quotes in this article: DNA  

Ellis expects the trial to reopen for enrollment after a 60-day review. Genentech will still follow through with a U.S. trial of Avastin plus Folfox, compared with Folfox alone, in a group of post-surgery later-stage colorectal cancer patients. Unlike the Avant study, this trial doesn't include a Xelox arm.

"This decision further underscores the belief that the safety concerns seen in Avant are limited to Xelox plus Avastin," according to Rodman & Renshaw's Mike King.

Avastin is already approved as a first-line treatment of metastatic colorectal cancer. The suspended study was reviewing the drug as a so-called adjuvant therapy designed to prevent the cancer from recurring.

Genentech's shares fell $2.04, or 2.4%, to $81.48 Monday.

  • Loading Comments...
  •  
1 2
Next >

SHARE:

  • email
  • print
  • comment
  • digg
  • delicious
  • linkedin

Recent Comments





Connect with TheStreet

Dow Jones S&P 500 NASDAQ 10-Year Note
10,309.92 1,091.49 2,138.44 32.31
Oil *
77.12
DOWN
154.48
DOWN
19.14
DOWN
37.61
DOWN
0.48
10 Yr
3.23%
SPDR Gold
115.06
-1.48%
-1.72%
-1.73%
-1.46%
Data delayed 20 minutes

Brokerage Partners

TheStreet Premium Services

All Services